A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium StudyHirva Mamdani, Shadia I. Jalal, Pashtoon Murtaza Kasi et al.|Frontiers in Oncology|2021Cited by 40
Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction AdenocarcinomaHirva Mamdani, Shadia I. Jalal, Bryan J. Schneider et al.|SSRN Electronic Journal|2021Cited by 0